Ovarian cancer progression is controlled by phenotypic changes in dendritic cells

Dendritic cells are transformed to become immunosuppressive during ovarian cancer progression.

[1]  I. Shih,et al.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.

[2]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[3]  W. Zou,et al.  Antigen-Presenting Cell (APC) Subsets in Ovarian Cancer , 2011, International reviews of immunology.

[4]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[5]  D. Gabrilovich,et al.  Myeloid-Derived Suppressor Cells in Human Cancer , 2010, Cancer journal.

[6]  B. Karlan,et al.  A role for BRCA1 in uterine leiomyosarcoma. , 2009, Cancer research.

[7]  C. Ahonen,et al.  In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. , 2009, Cancer research.

[8]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[9]  R. Buckanovich,et al.  Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. , 2008, Cancer research.

[10]  E. Huarte,et al.  PILAR is a novel modulator of human T-cell expansion. , 2008, Blood.

[11]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[12]  D. Tuveson,et al.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.

[13]  K. Gupta,et al.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer , 2007, Nature Medicine.

[14]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[15]  Kathleen R. Cho,et al.  Classification of Cancer Cell Lines Using an Automated Two-dimensional Liquid Mapping Method with Hierarchical Clustering Techniques* , 2006, Molecular & Cellular Proteomics.

[16]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Quynh-Mai Pham,et al.  Dendritic cells maximize the memory CD8 T cell response to infection. , 2005, Immunity.

[18]  A. Flesken-Nikitin,et al.  Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. , 2003, Cancer research.

[19]  Barbara C Vanderhyden,et al.  Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. , 2003, Cancer research.

[20]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[21]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[22]  Steffen Jung,et al.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. , 2002, Immunity.

[23]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[24]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[25]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[26]  B. Karlan,et al.  A Role for BRCA 1 in Uterine Leiomyosarcoma , 2009 .

[27]  T. Jacks,et al.  Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer , 2005, Nature Medicine.

[28]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[29]  A. Berchuck,et al.  Expression signatures of TP53 mutations in serous ovarian cancers , 2010, BMC Cancer.